Annogen starts a collaboration with another leading agricultural multinational to research non-coding regulatory DNA using SuRE™ screening technology.

PRESS RELEASE

The Netherlands, 26 January 2023

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with another top agricultural science and technology company to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The project will focus on genome-wide regulatory profiles under normal and stimulatory conditions. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
Agricultural biotech companies are constantly working on ways to up- or down regulate gene expression to influence traits of crops. Annogen’s services and technology contribute to these efforts by identifying the non-coding elements in the genome that underlie gene expression and repression as well as by performing mutagenesis screens on these elements to analyze the impact of non-coding mutations on gene expression.

While Annogen has its primary focus on medical applications like cell therapy and drug discovery, it has also established the applicability of its SuRE™ technology in animals and plants.

Joris van Arensbergen, founder and CEO, is pleased with another project in this field: “We now work with all the top tier agricultural firms, clearly illustrating the broad interest in harnessing the regulatory genome for crop improvement.”

About Annogen

At Annogen we use our SuRE™ technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene & cell therapy, as well as for recombinant protein production. In addition, we offer the AIM™ service to identify favorable gene insertions and their expression levels for more than 100,000 integrations in parallel. These approaches enables Research and Development to qualitatively interpret the non-coding genome in humans, animals and plants. For more information, please visit www.annogen.bio.

For further information

Victor Schut, CBO at Annogen, victor@annogen.bio, +31 614597016

Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance.

Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance.

Promoter design is becoming central to durable cell and gene therapy, as the field moves beyond delivery and toward precise expression control. Standard promoters like CMV or PGK often fail to solve key clinical challenges: off-target activity, “always-on” expression that can drive cellular exhaustion, and epigenetic silencing that shuts therapies down in vivo. Annogen’s SuRE™ platform addresses these bottlenecks by experimentally screening millions of non-coding DNA fragments in relevant models and refining designs with machine learning. The result is not a generic promoter, but a validated, non-viral promoter tailored for the specific tissue, condition, and therapeutic context.

VectorY’s Clinical Milestone and the Shift Toward Experimentally-Validated Promoters

VectorY’s Clinical Milestone and the Shift Toward Experimentally-Validated Promoters

The first patient dosing in VectorY Therapeutics’ PIONEER-ALS trial marks a definitive shift in gene therapy, moving past the “conservative” reliance on blunt viral promoters and the “digital guesses” of AI. While many rely on algorithms built from incomplete and insensitive data, VTx-002 is powered by an Annogen genome-derived promoter discovered through rigorous, large-scale experimental validation. This milestone proves that true therapeutic precision isn’t predicted in a black box—it is found by interrogating the genome directly to deliver the biological truth required for the clinic.

Technology

 

Solutions

 

Annogen